Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cost-effectiveness of treatment for chronic hepatitis C infection

Newer treatment options for hepatitis C are reasonably cost-effective, but results vary widely across patient subgroups and depend on quality-of-life assumptions, find researchers in this week's issue of the Journal of the American Medical Association.

News image

fiogf49gjkf04

Over 2.5 million people in the United States have chronic hepatitis C virus (HCV) infection.

However, as public health campaigns are pursued, a growing number of treatment candidates are likely to have minimal evidence of liver damage.

In this study, researchers examined the benefits and cost-effectiveness of treatments for chronic hepatitis C infection in asymptomatic, HCV sero-positive, but otherwise healthy individuals.

The team performed a cost-effectiveness analysis using a Markov model of the natural history of HCV infection and impact of treatment.

Probability of developing cirrhosis over a 30-year period was between 13% and 46% for men, and 1% and 29% for women.
Journal of the American Medical Association

They derived natural history parameters from an epidemiologic model. These were empirically calibrated to provide a good fit to observed data on both prevalence of HCV seropositivity and time trends in outcomes.

The researchers assessed cohorts of 40-year-olds who had elevated levels of alanine aminotransferase, positive HCV RNA assays and serologic tests for antibody to HCV. Subjects had no histological evidence of fibrosis on liver biopsy.

The subjects were treated using either standard or pegylated interferon alfa-2b, or combination therapy with standard or pegylated interferon plus ribavirin.

The team evaluated the lifetime costs of treatment, life expectancy, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.

The researchers found that the probability of patients with chronic HCV developing cirrhosis over a 30-year period was between 13% and 46% for men, and 1% and 29% for women.

They determined that the incremental cost-effectiveness of combination therapy with pegylated interferon for men was between $26,000 and $64,000 per QALY for genotype 1, and between $10,000 and $28,000 for other genotypes.

The cost-effectiveness for women was between $32,000 and $90,000 for genotype 1, and between $12,000 and $42,000 for other genotypes.

The research team found that the benefits of treatment were largely improvements in health-related quality of life, rather than prolonged survivorship, meaning that cost-effectiveness ratios expressed as dollars per year of life were substantially higher.

In addition, results were most sensitive to assumptions about the gains and decrements in health-related quality of life associated with treatment.

Dr Joshua Salomon's team concluded, "While newer treatment options for hepatitis C appear to be reasonably cost-effective on average, these results vary widely across different patient subgroups and depend critically on quality-of-life assumptions".

"As the pool of persons eligible for treatment for HCV infection expands to the more general population, it will be imperative for patients and their physicians to consider these assumptions in making individual-level treatment decisions".

JAMA 2003; 290(2): 228-37
10 July 2003

Go to top of page Email this page Email this page to a colleague

 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 11 May 2018 
Depressive symptoms in IBD youth
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
PPI use and cognitive decline
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Fecal incontinence and quality of life in IBD
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 24 April 2018 
PPI and risk of stroke
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 20 April 2018 
Worldwide H.pylori prevalence
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us